TGF-β impairs renal autoregulation via generation of ROS

American Journal of Physiology - Renal Physiology

Volumn 288, Issue 5 57-5, 2005, Pages

  Sharma, Kumar ^a,c   Cook, Anthony ^b   Smith, Matt ^a   Valancius, Cathryn ^a   Inscho, Edward W ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Growth factors; Hypertension; Kidney disease; NADPH oxidase; Oxidative stress; Renal hemodynamics

Indexed keywords

APOCYNIN; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOREGULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; EXPERIMENTAL TEST; EXPOSURE; GLOMERULUS CAPILLARY; INTERMETHOD COMPARISON; JUXTAGLOMERULAR APPARATUS; KIDNEY ARTERY; KIDNEY DYSFUNCTION; KIDNEY PERFUSION; MALE; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; RAT; SMOOTH MUSCLE FIBER; STIMULATION; TECHNIQUE; VASCULAR SMOOTH MUSCLE; VIDEORECORDING;

EID: 17644408006     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00345.2004     Document Type: Article

References (48)

1. Alebiosu CO. An update on "progression promoters" in renal diseases. J Natl Med Assoc 95: 30-42, 2003.
2. 1 regulates gene expression of its own converting enzyme furin. J Clin Invest 99: 1974-1983, 1997.
3. Border W and Noble N. Transforming growth factor β in tissue fibrosis. N Engl J Med 331: 1286-1292, 1994.
4. Carmines P, Ohishi K, and Ikenaga H. Functional impairment of renal afferent arteriolar voltage-gated calcium channels in rats with diabetes mellitus. J Clin Invest 98: 2564-2571, 1996.
5. Dahly AJ, Hoagland KM, Flasch KA, Jha S, Ledbetter SR, and Roman RJ. Antihypertensive effects of chronic anti-TGF-β antibody therapy in Dahl S rats. Am J Physiol Regul Integr Comp Physiol 283: R757-R767, 2002.
6. 1 on renal extracellular matrix components and their regulating proteins. J Am Soc Nephrol 10: 2109-2119, 1999.
7. Duque I, Garcia-Escribano C, Rodriguez-Puyol M, Diez-Marques ML, Lopez-Novoa JM, Arribas I, Hernando L, and Rodriguez-Puyol D. Effects of reactive oxygen species on cultured rat mesangial cells and isolated rat glomeruli. Am J Physiol Renal Fluid Electrolyte Physiol 263: F466-F473, 1992.
8. Faber-Elman A, Solomon A, Abraham JA, Marikovsky M, and Schwartz M. Involvement of wound-associated factors in rat brain astrocyte migratory response to axonal injury: in vitro simulation. J Clin Invest 97: 162-171, 1996.
9. Flyvbjerg A, Bornfeldt KE, Marshall SM, Arnqvist HJ, and Orskov H. Kidney IGF-I mRNA in initial renal hypertrophy in experimental diabetes in rats. Diabetologia 33: 334-338, 1990.
10. Flyvbjerg A, Mogensen CE, Osterby R, and Orskov H. Renal hypertrophy in experimental diabetes. J Diabetes Complications 5: 62-64, 1991.
11. 2-macroglobulin are responsible for the binding of nerve growth factor-β, platelet-derived growth factor-BB, and transforming growth factor-βB. J Biol Chem 275: 5826-5831, 2000.
12. Grainger DL, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, and Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein a. Science 260: 1655-1658, 1993.
13. 2 accumulation in the juxtaglomerular apparatus of mouse kidney. J Clin Invest 88: 2117-2122, 1991.
14. Hostetter T, Brenner B, and Meyer TW. Milestones in nephrology. J Am Soc Nephrol 12: 1315-1325, 2001.
15. Hostetter T, Rennke H, and Brenner B. The case for intrarenal hypertension in the initiation and progression of diabetic and other gomerulopathies. Am J Med 72: 375-380, 1982.
16. Imig JD and Inscho EW. Adaptations to the renal microcirculation in hypertension. Microcirculation 9: 315-328, 2002.
17. 2-purinoreceptor agonists. Am J Physiol Renal Physiol 274: F1077-F1085, 1998.
18. Inscho E, Imig J, Deichmann P, and Cook AK. Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats. J Am Soc Nephrol 10, Suppl 11: S178-S183, 1999.
19. 2-purinoceptor activation. Am J Physiol Renal Fluid Electrolyte Physiol 271: F1077-F1085, 1996.
20. Inscho EW, LeBlanc EA, Pham BT, White SM, and Imig JD. Purinoceptor-mediated calcium signaling in preglomerular smooth muscle cells. Hypertension 33: 195-200, 1999.
21. Islam M, Burke J, McGowan T, Zhu Y, Dunn S, McCue P, Kanalas J, and Sharma K. Effect of anti-transforming growth factor-β antibodies in cylcosporine-induced renal dysfunction. Kidney Int 59: 498-506, 2001.
22. Keller G, Zimmer G, Mall G, Ritz E, and Amann K. Nephron number in patients with primary hypertension. N Engl J Med 348: 101-108, 2003.
23. Kirschenlohr H, Metcalfe J, Weissberg P, and Grainger D. Adult human aortic smooth muscle cells in culture produce active TGF-β. Am J Physiol Cell Physiol 265: C571-C576, 1993.
24. Kriz W, Hosser H, Hahnel B, Simons J, and Provoost A. Development of vascular pole-associated glomerulosclerosis in the fawn-hooded rat. J Am Soc Nephrol 9: 381-396, 1998.
25. Kroustrup H, Gundersen H, and Osterby R. Glomerular size and structure in diabetes mellitus. Diabetologia 13: 207-210, 1977.
26. Lin JJ, Tonshoff B, Bouriquet N, Casellas D, Kaskel FJ, and Moore LC. Insulin-like growth factor-I restores microvascular autoregulation in experimental chronic renal failure. Kidney Int Suppl 67: S195-S198, 1998.
27. Liu Y, Rajur K, Tolbert E, and Dworkin LD. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways. Kidney Int 58: 2028-2043, 2000.
28. Lund DD, Faraci FM, Miller FJ, and Heistad MD. Gene transfer of endothelial nitric oxide synthase improves relaxation of carotid arteries from diabetic rabbits. Circulation 101: 1027-1033, 2000.
29. Marumo T, Schini-Kerth V, Fisslthaltr B, and Busse R. Platelet-derived growth factor-stimulated superoxide anion production modulates activation of transcription factor NF-kB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation 96: 2361-2367, 1997.
30. Nakamura S, Fukui M, Ebihara I, Osada S, Nagaoka I, Tomino Y, and Koide H. mRNA expression of growth factors in glomeruli from diabetic rats. Diabetes 42: 450-456, 1993.
31. National Institute of Diabetes and Digestive and Kidney Diseases. USRDS 2000 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetic and Digestive Kidney Disease, National Institutes of Health, 2000.
32. Ortiz MC, Manriquez MC, Romero JC, and Juncos LA. Antioxidants block angiotensin ii-induced increases in blood pressure and endothelin. Hypertension 38: 655-659, 2001.
33. Osterby R, Tapia J, Nyberg G, Tencer J, Willner J, Rippe B, and Torffvit O. Renal structures in type 2 diabetic patients with elevated albumin excretion rate. APMIS 109: 751-761, 2001.
34. Palmer BF. Renal dysfunction complicating the treatment of hypertension. N Engl J Med 347: 1256-1261, 2002.
35. 2. Contrib Nephrol 118: 238-248, 1996.
36. Schmidt K, Pesce C, Liu Q, Nelson RG, Bennett PH, Karnitschnig H, Striker LJ, and Striker GE. Large glomerular size in Pima Indians: lack of change with diabetic nephropathy. J Am Soc Nephrol 3: 229-235, 1992.
37. Schnackenberg CG. Oxygen radicals in cardiovascular-renal disease. Curr Opin Pharmacol 2: 121-125, 2002.
38. Schnackenberg CG. Physiological and pathophysiological roles of oxygen radicals in the renal microvasculature. Am J Physiol Regul Integr Comp Physiol 282: R335-R342, 2002.
39. Schoonmaker GC, Fallet RW, and Carmines PK. Superoxide anion curbs nitric oxide modulation of afferent arteriolar ANG II responsiveness in diabetes mellitus. Am J Physiol Renal Physiol 278: F302-F309, 2000.
40. Sharma K, Deelman L, Madesh M, Kurz B, Ciccone E, Siva S, Hu T, Zhu Y, Wang L, Henning R, Ma X, and Hajnociky G. Involvement of transforming growth factor-β in regulation of calcium transients in diabetic vascular smooth muscle cells. Am J Physiol Renal Physiol 285: F1258-F1270, 2003.
41. Sharma K, Guo J, Jin Y, and Ziyadeh FN. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45: 522-530, 1996.
42. Stein-Oakley AN, Maguire JA, Dowling J, Perry G, and Thomsom NM. Altered expression of fibrogenic growth factors in IgA nephropathy and focal and segmental glomerulosclerosis. Kidney Int 51: 195-204, 1997.
43. 2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression. Cancer Res 64: 6402-6409, 2004.
44. Wang SN, LaPage J, and Hirschberg R. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Int 57: 1002-1014, 2000.
45. 1 receptors in renal hemodynamics and oxygenation in the postclipped 2K,1C kidney. Hypertension 41: 692-696, 2003.
46. Wilcox CS and Welch WJ. Interaction between nitric oxide and oxygen radicals in regulation of tubuloglomerular feedback. Acta Physiol Scand 168: 119-124, 2000.
47. Yamamoto T, Noble NA, Cohen AH, Nast CC, Hishida A, Gold LI, and Border WA. Expression of transforming growth factor-β isoforms in human glomerular diseases. Kidney Int 49: 461-469., 1996.
48. Ziyadeh F, Hoffman B, Ban D, Iglesias-de la Cruz C, Hong S, Isono M, Chen S, McGowan T, and Sharma K. Long-term prevention of renal insufficiency excess matrix gene expression and glomerular mesangial matrix expansion by treatment with monoclonal anti-ransforming growth factor-β antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97: 8015-8020, 2000.